Cargando…
Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy
Immune checkpoint inhibitors (ICIs) may cause immune-related adverse events (IRAEs). Characterisation and data on treatment of musculoskeletal IRAEs are scarce. In this cohort study, patients receiving ICI therapy who experienced arthralgia were evaluated for the presence of synovitis. Data on demog...
Autores principales: | Leipe, Jan, Christ, Lisa A, Arnoldi, Andreas P, Mille, Erik, Berger, Frank, Heppt, Markus, Goldscheider, Ilana, Kauffmann-Guerrero, Diego, Huber, Rudolf M, Dechant, Claudia, Berking, Carola, Schulze-Koops, Hendrik, Skapenko, Alla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109812/ https://www.ncbi.nlm.nih.gov/pubmed/30167328 http://dx.doi.org/10.1136/rmdopen-2018-000714 |
Ejemplares similares
-
Regulatory T cells in rheumatoid arthritis
por: Leipe, Jan, et al.
Publicado: (2005) -
The role of the T cell in autoimmune inflammation
por: Skapenko, Alla, et al.
Publicado: (2005) -
Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity
por: Calabrese, C, et al.
Publicado: (2017) -
Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm
por: Schulze-Koops, Hendrik, et al.
Publicado: (2017) -
COVID-19 vaccination in individuals with inflammatory rheumatic diseases
por: Skapenko, Alla, et al.
Publicado: (2022)